Newsfeeds - Spark Newswire

1 minute read

News

Reuters Reported Earlier: Vaccine Makers, Including GSK, Moderna, Sanofi Developing Bird Flu Shots For Humans

Today, 2:36 AM

https://www.reuters.com/business/healthcare-pharmaceuticals/vaccine-makers-prep-bird-flu-shot-humans-just-case-rich-nations-lock-supplies-2023-03-20/

GSK

1 minute read

FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s

By Vandana Singh

Today, 2:36 AM

The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…

GSK

2 minute read

Wall Street’s Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields

By Lisa Levin

Today, 2:36 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

ABBV

1 minute read

GSK/Pfizer-Backed ViiV Healthcare’s HIV Treatment At Par With Gilead’s: Study Shows

By Vandana Singh

Today, 2:36 AM

ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…

GILD

1 minute read

GSK, Pfizer And Shionogi Owned ViiV Healthcare Announced 12-month Findings From The Solar Phase 3B Head-to-head Study Of Long Acting Cabenuva Regime (CAB+RPV LA) Compared Against Gilead’s Biktarvy Regime (BIC/FTC/TAF)

By Benzinga Newsdesk

Today, 2:36 AM

Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV

GSK

5 minute read

EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue

By Nicolas Jose Rodriguez

Today, 2:36 AM

Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among the alternatives to create value. In addition, cannabis companies might look at risk mitigation as an alternative to achieve higher quality and prevent losses.

BAYRY

1 minute read

JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals

By Vandana Singh

Today, 2:36 AM

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) received written notice from Janssen, a unit of Johnson & Johnson (NYSE:JNJ), to terminate their rights to JNJ-75220795, now called…

ARWR

1 minute read

GSK’s Jemperli Won US FDA Approval For Treatment Of Mismatch Repair-Deficient (Dmmr) Recurrent Or Advanced Endometrial Cancer

By Benzinga Newsdesk

Today, 2:36 AM

GSK plc (NYSE:GSK) today reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR)

GSK

1 minute read